# IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy

> **NCT05110495** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 27 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Xentuzumab

## Key facts

- **NCT ID:** NCT05110495
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-05-27
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110495, "IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05110495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*